167 related articles for article (PubMed ID: 31778110)
1. Engineering of an Iranian
Nikbin VS; Keramati M; Noofeli M; Tayebzadeh F; Kahali B; Shahcheraghi F
J Med Microbiol; 2020 Jan; 69(1):111-119. PubMed ID: 31778110
[No Abstract] [Full Text] [Related]
2. Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated Pertussis Toxin and Pertactin by unmarked allelic exchange.
Buasri W; Impoolsup A; Boonchird C; Luengchaichawange A; Prompiboon P; Petre J; Panbangred W
BMC Microbiol; 2012 Apr; 12():61. PubMed ID: 22524455
[TBL] [Abstract][Full Text] [Related]
3. [Engineering of attenuated Bordetella pertussis bacteria producing immunogenic non-toxic form of pertussis toxin].
Siniashina LN; Nechaeva EV; Amelina IP; Karataev GI
Zh Mikrobiol Epidemiol Immunobiol; 2009; (6):89-94. PubMed ID: 20095432
[TBL] [Abstract][Full Text] [Related]
4. Development of safer pertussis DNA vaccine expressing non-toxic C180 polypeptide of pertussis toxin S1 subunit.
Kamachi K; Arakawa Y
Vaccine; 2007 Jan; 25(6):1000-6. PubMed ID: 17050047
[TBL] [Abstract][Full Text] [Related]
5. Characterization of pertussis toxin analogs containing mutations in B-oligomer subunits.
Loosmore S; Zealey G; Cockle S; Boux H; Chong P; Yacoob R; Klein M
Infect Immun; 1993 Jun; 61(6):2316-24. PubMed ID: 8500874
[TBL] [Abstract][Full Text] [Related]
6. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains.
Bottero D; Gaillard ME; Fingermann M; Weltman G; Fernández J; Sisti F; Graieb A; Roberts R; Rico O; Ríos G; Regueira M; Binsztein N; Hozbor D
Clin Vaccine Immunol; 2007 Nov; 14(11):1490-8. PubMed ID: 17699837
[TBL] [Abstract][Full Text] [Related]
7. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization.
Hausman SZ; Burns DL
Infect Immun; 2000 Jun; 68(6):3763-7. PubMed ID: 10816544
[TBL] [Abstract][Full Text] [Related]
8. Genetically detoxified pertussis toxin displays near identical structure to its wild-type and exhibits robust immunogenicity.
Ausar SF; Zhu S; Duprez J; Cohen M; Bertrand T; Steier V; Wilson DJ; Li S; Sheung A; Brookes RH; Pedyczak A; Rak A; Andrew James D
Commun Biol; 2020 Aug; 3(1):427. PubMed ID: 32759959
[TBL] [Abstract][Full Text] [Related]
9. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.
Feunou PF; Ismaili J; Debrie AS; Huot L; Hot D; Raze D; Lemoine Y; Locht C
Vaccine; 2008 Oct; 26(45):5722-7. PubMed ID: 18762220
[TBL] [Abstract][Full Text] [Related]
10. [Antigenic variability of Bordetella pertussis strains isolated in 1967-2010 in the Czech Republic--possible explanation for the rise in cases of pertussis?].
Zavadilová J; Lžičařová D; Musílek M; Křížová P; Fabiánová K
Epidemiol Mikrobiol Imunol; 2015 Sep; 64(3):130-8. PubMed ID: 26448300
[TBL] [Abstract][Full Text] [Related]
11. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
[TBL] [Abstract][Full Text] [Related]
12. Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan.
Kodama A; Kamachi K; Horiuchi Y; Konda T; Arakawa Y
J Clin Microbiol; 2004 Dec; 42(12):5453-7. PubMed ID: 15583264
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of Bordetella pertussis strains toxicity in vitro using CHO cell lines].
Zawadka M; Rabczenko D; Lutyńska A
Med Dosw Mikrobiol; 2014; 66(3-4):185-94. PubMed ID: 25804072
[TBL] [Abstract][Full Text] [Related]
14. [Construction of the genetically attenuated bacteria Bordetella pertussis devoid of dermonecrotic toxin activity and producing modified nontoxic pertussis toxin form].
Siniashina LN; Siniashina LS; Semin EG; Amelina IP; Karataev GI
Mol Gen Mikrobiol Virusol; 2010; (3):31-6. PubMed ID: 20886687
[TBL] [Abstract][Full Text] [Related]
15. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
[TBL] [Abstract][Full Text] [Related]
16. DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice.
Kamachi K; Konda T; Arakawa Y
Vaccine; 2003 Nov; 21(31):4609-15. PubMed ID: 14575775
[TBL] [Abstract][Full Text] [Related]
17. Genome characteristics of
Ben Fraj I; Bouchez V; Smaoui H; Kechrid A; Brisse S
J Med Microbiol; 2019 Sep; 68(9):1320-1323. PubMed ID: 31329091
[TBL] [Abstract][Full Text] [Related]
18. Genetic and antigenic analysis of Bordetella pertussis isolates recovered from clinical cases in Ontario, Canada, before and after the introduction of the acellular pertussis vaccine.
Tsang RS; Sill ML; Martin IE; Jamieson F
Can J Microbiol; 2005 Oct; 51(10):887-92. PubMed ID: 16333349
[TBL] [Abstract][Full Text] [Related]
19. Bordetella pertussis from functional genomics to intranasal vaccination.
Locht C; Antoine R; Raze D; Mielcarek N; Hot D; Lemoine Y; Mascart F
Int J Med Microbiol; 2004 Apr; 293(7-8):583-8. PubMed ID: 15149035
[TBL] [Abstract][Full Text] [Related]
20. Strain variation and antigenic divergence among Bordetella pertussis circulating strains isolated from patients in Iran.
Sadeghpour Heravi F; Nikbin VS; Nakhost Lotfi M; Badiri P; Jannesar Ahmadi N; Zahraei SM; Shahcheraghi F
Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1893-1900. PubMed ID: 30094521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
